uniQure (QURE) Expected to Announce Quarterly Earnings on Thursday

uniQure (NASDAQ:QURE) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect uniQure to post earnings of ($0.93) per share and revenue of $4.8350 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

uniQure Stock Performance

uniQure stock opened at $23.43 on Thursday. The firm has a 50 day simple moving average of $23.43 and a 200-day simple moving average of $29.29. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -5.34 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50.

Insiders Place Their Bets

In related news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. CIBC Private Wealth Group LLC purchased a new stake in uniQure in the 3rd quarter valued at $50,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $48,000. Ensign Peak Advisors Inc boosted its stake in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the period. Knott David M Jr boosted its stake in shares of uniQure by 100.0% during the fourth quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after buying an additional 2,000 shares during the period. Finally, Deutsche Bank AG grew its holdings in shares of uniQure by 98.3% during the fourth quarter. Deutsche Bank AG now owns 4,621 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,291 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Market context — QURE has seen elevated volume and technical attention (50-day ~$23.43 vs. 200-day ~$29.29; 12-month low $7.76 / high $71.50), which may amplify reactions to legal headlines.
• Negative Sentiment: Multiple law firms have filed or announced class actions alleging securities fraud for purchases between Sept. 24, 2025 and Oct. 31, 2025; Rosen Law Firm is soliciting lead plaintiffs and reminding investors of upcoming deadlines. Rosen Law Notice
• Negative Sentiment: Several other prominent plaintiff firms (Berger Montague, Levi & Korsinsky, Faruqi & Faruqi, Pomerantz, Kessler Topaz, Gross Law, et al.) have issued notices or filed suits, increasing the likelihood of consolidated litigation and plaintiff competition for leadership. Gross Law Notice
• Negative Sentiment: Allegations behind the suits focus on an FDA approval delay and claims that uniQure misled investors about its pivotal study design and regulatory timing — specific allegations include that the pivotal study comparisons and BLA timeline were not fully cleared by the FDA. Such claims raise the prospect of material disclosures, remediation costs, and reputational damage. KSF Notice (FDA delay)
• Negative Sentiment: Firms are warning investors of an April 13, 2026 deadline to apply for lead-plaintiff status; consolidation and lead plaintiff selection could shape case strategy and potential settlements. Levi & Korsinsky Notice

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Leerink Partners reduced their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 10th. William Blair restated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Finally, Mizuho cut their target price on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $58.33.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.